Cookies on the Economic Times website

Economic Times has updated its Privacy and Cookie policy. We use cookies to ensure that we give you the better experience on our website. If you continue without changing your settings,we'll assume that you are happy to receive all cookies on the Economic Times website. However, you can change your cookie setting at any time by clicking on our Cookie Settings at any time.You can also see our Privacy Policy

Pharmaceuticals

India to review use of remdesivir, hydroxychloroquine for Covid therapy

AFP

Synopsis

Indian Council of Medical Research (ICMR) director general Balram Bhargava told ET that clinical protocols will be updated after discussions with the National Task Force (NTF) and the joint monitoring group.

By , ET Bureau
6 mins read,
New Delhi: India will review its clinical management protocol for Covid-19 in the wake of a preliminary World Health Organisation (WHO) report suggesting that remdesivir and hydroxychloroquine (HCQ) appear to have little effect on the mortality of hospitalised patients. However, remdesivir trials will continue in India and elsewhere.“Until and unless there is a directive from the drug regulatory authority, the trials will continue,” said Samiran

To Read the Full Story, Become an ET Prime Member

Access the exclusive Economic Times stories, Editorial and Expert opinion

START FREE TRIAL

Why

  • Sharp Insight-rich, Indepth stories across 20+ sectors

  • Access the exclusive Economic Times stories, Editorial and Expert opinion

  • Clean experience with
    Minimal Ads
  • Comment & Engage with ET Prime community
  • Exclusive invites to Virtual Events with Industry Leaders
  • A trusted team of Journalists & Analysts who can best filter signal from noise
START FREE TRIAL